One-year outcomes of transcatheter tricuspid valve repair with the Mistral device

Transcatheter tricuspid valve intervention (TTVI) has become a valuable treatment option and may be considered in inoperable patients with severe symptomatic tricuspid regurgitation (TR) and a suitable anatomy in whom improvement can be expected1. We present the long-term clinical outcomes of the Mistral device (Mitralix Ltd.), which is used to treat patients with severe functional TR.

The Mistral device is a helix-shaped nitinol wire and allows, in the ideal case, the approximation of all three tricuspid leaflets with one single implant through the inward pulling of the chordae tendineae and subsequent leaflet coaptation. The placement of more than one device is possible and might be preferred in some cases to reduce TR sufficiently. A detailed description can be found elsewhere2. Patients were scheduled to undergo follow-up visits at 30 days, and 3, 6, 12 and 24 months after device implantation. The change in New York Heart Association (NYHA) Class, 6-minute walk test (6MWT) distance, and Kansas City Cardiomyopathy Questionnaire (KCCQ) score was recorded. Echocardiographic data were analysed in an independent core lab.

Ethical oversight was secured for our...